Academic Section(s):
Gynecologic Oncology
Education:
- Ph.D. Life Science, Department of Endocrinology and Drug Target Discovery and Development), CSIR-CDRI/Jawaharlal Nehru University, India
- Master of Science- Biotechnology, V.B.S. P. University, Jaunpur, UP, India
- Bachelor of Science in Chemistry, Botany from D.D.U. Gorakhpur University, Gorakhpur, UP, India
Positions/Scientific Appointments
2005-2007 Research Assistant, VP Chest Institute, University of Delhi, Delhi – 07, India
2007-2009 Junior Research Fellow, CSIR-CDRI Lucknow, UP, India
2009-2012 Senior Research Fellow, CSIR-CDRI Lucknow, UP, India
2012- 2013 Assistant Professor, Department of Biotechnology, IT College, Lucknow, UP India
2013-2018 Postdoctoral Research Fellow, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
2018- 2023 Assistant Professor of Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
2023-Present Assistant Professor, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Memberships:
Associate member of Stephenson Cancer Center (Cancer Biology research program)
Clinical/Research Interests:
For the past 15 years, I have devoted my research to developing novel therapeutic approaches for targeting cancer. Non-coding RNAs are known to play a key role in the development of gynecological malignancies like ovarian cancer and uterine carcinosarcoma. However, their therapeutic potential has not been well explored and is the focus of my ongoing research. Additionally, I am also exploring non-coding RNA's (long non-coding RNA and micro-RNA) role in cancer metabolism, as well as in the tumor microenvironment. My lab's primary objective is to gain a deeper understanding of molecular pathways governed by non-coding RNAs and apply these discoveries to improve cancer diagnosis and treatment. My research ultimately aims to produce novel non-coding RNA-based therapeutic strategies for cancer-afflicted patients.
Funding:
PHF Pilot Grant (July 2022-June 2023)
Tittle - Dissecting the role of miR-195 in ovarian cancer stemness
Role: Principal Investigator
OCAST FY21 Competition Health Research Award (November 2021 to October 2024),
Tittle - Targeting NNT-AS1 for Ovarian Cancer Therapy.
Role: Principal Investigator
NCI-R21 (1R21CA280507-01)
Role of miR-195 in Chemo-Resistant Ovarian Cancer
Role: Principal Investigator
DoD OCA-ECI (09/01/2023-08/31/2027)
Title: miR-195 Re-Expression: A Therapeutic Strategy for Chemo-Resistant Ovarian Cancer
Role: Principal Investigator
Select Honors & Accomplishments:
- Associate member of Stephenson Cancer Center (Cancer Biology research program)
- Bruce Patsner Grant Award for Innovative Research & Technology (April 2017 to April 2018), from the Foundation for Women’s Cancer supported by the Dr. Bruce Patsner.
- Qualified for Fellowship by Indian Council for Medical Research (ICMR), Government of India, 2007
- Qualified in the National Eligibility Test (NET) and declared eligible for Fellowship and Lectureship by Council for Scientific and Industrial Research (CSIR), Government of India, 2006
Select Publications:
- Rao, G., S.K.D. Dwivedi, Y. Zhang, A. Dey, K. Shameer, R. Karthik, S. Srikantan, M.N. Hossen, J.D. Wren, M. Madesh, J.T. Dudley, R. Bhattacharya, and P. Mukherjee, MicroRNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Rep, 2020. 21(10): p. e48483. PMC7534609
- Dwivedi, S.K.D., G. Rao, A. Dey, P. Mukherjee, J.D. Wren, and R. Bhattacharya, Small Non-Coding-RNA in Gynecological Malignancies. Cancers (Basel), 2021. 13(5). PMC7961667
- Neizer-Ashun, F., S.K.D. Dwivedi, A. Dey, E. Thavathiru, W.L. Berry, S.P. Lees-Miller, P. Mukherjee, and R. Bhattacharya, KRCC1, a modulator of the DNA damage response. Nucleic Acids Res, 2022. 50(19): p. 11028-11039. PMC9638924
- Zhang, Y., C.K. Elechalawar, W. Yang, A.N. Frickenstein, S. Asfa, K.M. Fung, B.N. Murphy, S.K. Dwivedi, G. Rao, A. Dey, S. Wilhelm, R. Bhattacharya, and P. Mukherjee, Disabling partners in crime: Gold nanoparticles disrupt multicellular communications within the tumor microenvironment to inhibit ovarian tumor aggressiveness. Mater Today (Kidlington), 2022. 56: p. 79-95. PMC9523457
- Dwivedi, S.K.D., K. Shameer, A. Dey, S.B. Mustafi, X. Xiong, U. Bhattacharya, F. Neizer-Ashun, G. Rao, Y. Wang, C. Ivan, D. Yang, J.T. Dudley, C. Xu, J.D. Wren, P. Mukherjee, and R. Bhattacharya, KRCC1: A potential therapeutic target in ovarian cancer. FASEB J, 2020. 34(2): p. 2287-2300. PMC7018556
- Hossen, M.N., L. Wang, S.K.D. Dwivedi, Y. Zhang, G. Rao, C.K. Elechalwar, V. Sheth, A. Dey, S. Asfa, S.K. Gulla, C. Xu, K.M. Fung, J.D. Robertson, M. Bieniasz, S. Wilhelm, R. Bhattacharya, and P. Mukherjee, Gold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth. Adv Sci (Weinh), 2022. 9(31): p. e2200491. PMC9631030
- Banerjee Mustafi, S., P.K. Chakraborty, S.K. Dwivedi, K. Ding, K.M. Moxley, P. Mukherjee, and R. Bhattacharya, BMI1, a new target of CK2alpha. Mol Cancer, 2017. 16(1): p. 56. PMC5341428
- Chakraborty, P.K., S.B. Mustafi, X. Xiong, S.K.D. Dwivedi, V. Nesin, S. Saha, M. Zhang, D. Dhanasekaran, M. Jayaraman, R. Mannel, K. Moore, S. McMeekin, D. Yang, R. Zuna, K. Ding, L. Tsiokas, R. Bhattacharya, and P. Mukherjee, MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun, 2017. 8: p. 14634. PMC5477507
- Dwivedi, S.K., S.B. Mustafi, L.S. Mangala, D. Jiang, S. Pradeep, C. Rodriguez-Aguayo, H. Ling, C. Ivan, P. Mukherjee, G.A. Calin, G. Lopez-Berestein, A.K. Sood, and R. Bhattacharya, Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget, 2016. 7(12): p. 15093-104. PMC4924772
Publication Link:
https://www.ncbi.nlm.nih.gov/myncbi/shailendra.dwivedi.1/bibliography/public/